Hyperfine, Inc. (NASDAQ:HYPR) Receives Consensus Rating of “Hold” from Brokerages

Posted by George Bondi on Sep 12th, 2026

Hyperfine, Inc. (NASDAQ:HYPR – Get Free Report) has received a consensus recommendation of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $2.0333.

HYPR has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Hyperfine in a research report on Friday, July 17th. B. Riley Financial reissued a “buy” rating and set a $1.60 target price (down from $2.00) on shares of Hyperfine in a report on Monday, August 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $2.00 price target on shares of Hyperfine in a report on Thursday, August 20th.

Read Our Latest Stock Report on Hyperfine

Hedge Funds Weigh In On Hyperfine

A number of large investors have recently modified their holdings of HYPR. Vanguard Group Inc. increased its holdings in Hyperfine by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 3,511,972 shares of the company’s stock worth $5,092,000 after acquiring an additional 190,136 shares during the period. Tortoise Investment Management LLC boosted its stake in Hyperfine by 60.0% during the fourth quarter. Tortoise Investment Management LLC now owns 72,000 shares of the company’s stock valued at $71,000 after buying an additional 27,000 shares during the period. Geode Capital Management LLC grew its position in Hyperfine by 21.4% during the fourth quarter. Geode Capital Management LLC now owns 815,986 shares of the company’s stock worth $799,000 after buying an additional 143,975 shares in the last quarter. Cerity Partners LLC purchased a new position in Hyperfine during the fourth quarter worth about $59,000. Finally, Renaissance Technologies LLC increased its stake in Hyperfine by 674.4% in the 4th quarter. Renaissance Technologies LLC now owns 364,743 shares of the company’s stock worth $357,000 after acquiring an additional 317,645 shares during the last quarter. 15.03% of the stock is currently owned by institutional investors.

Hyperfine Trading Up 0.5%

NASDAQ:HYPR opened at $0.79 on Friday. Hyperfine has a 12 month low of $0.78 and a 12 month high of $2.22. The company has a current ratio of 6.15, a quick ratio of 5.45 and a debt-to-equity ratio of 0.36. The firm’s 50 day moving average is $0.93 and its 200 day moving average is $1.20. The stock has a market capitalization of $83.79 million, a PE ratio of -2.08 and a beta of 1.41.

Hyperfine (NASDAQ:HYPR – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). The firm had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $4.13 million. Hyperfine had a negative return on equity of 97.88% and a negative net margin of 210.75%. Sell-side analysts expect that Hyperfine will post -0.34 earnings per share for the current year.

Hyperfine Company Profile

(Get Free Report)

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.